Certara Inc, a biosimulation software company, filed Form S-1 Registration Statement on November 18, 2020 with the U.S. Securities and Exchange Commission to raise up to $100 million IPO. Pricing terms are yet to announce. Sources estimate the total proceeds raised would up to $500 million.
The company provides an integrated, end-to-end platform used by more than 1,600 biopharmaceutical companies and academic institutions across 60 countries, including all of the top 35 biopharmaceutical companies by R&D spend in 2019.
The Princeton, New Jersey-based company was founded in 2007 and booked $233 million in revenue for the 12 months ended September 30, 2020. It plans to list on the Nasdaq Global Select Market under the symbol “CERT.” Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays, and William Blair are underwriters of the IPO.
The company engages Simpson Thacher & Bartlett LLP as US Securities Counsel, and CohnReznick LLP as Independent Auditor.
#ipo #nasdaq #certara #biosimulation #software
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected].
